-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Narazaciclib in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Narazaciclib in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Narazaciclib in Endometrial Cancer Drug Details: ON-123300 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABD-3001 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABD-3001 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABD-3001 in Myelodysplastic Syndrome Drug Details:ABD-3001 (sefaldin) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABD-3001 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABD-3001 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABD-3001 in Relapsed Acute Myeloid Leukemia Drug Details:ABD-3001 (sefaldin) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABD-3001 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABD-3001 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABD-3001 in Refractory Acute Myeloid Leukemia Drug Details:ABD-3001 (sefaldin) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Gliosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Gliosarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent....
-
Sector Analysis
Traditional Wound Management Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Traditional Wound Management Market Report Overview The traditional wound management market size was $6.45 billion in 2023. Factors such as the usage of traditional wound dressings at home for mild cuts and burns and increasing epidemiology conditions will drive the market growth at a CAGR of more than 3% during 2023-2033. Traditional wound management involves dry dressings that cover and protect the wound from infection, thus avoiding a moist wound environment. They are used as primary or secondary dressings or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria Drug Details:RLYB-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLYB-116 in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RLYB-116 in Myasthenia Gravis Drug Details:RLYB-116 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPB-111077 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPB-111077 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPB-111077 in Acute Myelocytic Leukemia (AML,...
-
Company Profile
Centene Corp – Company Profile
Centene Corp (Centene) is a healthcare service provider that offers services to government-sponsored healthcare programs with a focus on underinsured and uninsured individuals. Centene provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts, and other health solutions through its specialty services companies. It provides a comprehensive range of managed healthcare products and services including Medicaid, the State Children's Health Insurance Program (CHIP), Long Term Care (LTC), Foster Care, dual-eligible individuals (Duals), the Aged, blind or disabled program (ABD),...
Add to Basket